MD&A Q2_2020 (Eng ) July 31, 2020 Subject : Interim Management Discussion and Analysis of Q2/2020 Attention : President of The Stock Exchange of Thailand We attach herewith the financial statements

ที่ FPI Ref. FPI.008/2020 11 August 2020 Subject : Management Discussion & Analysis of Performance Results of Quarter 2 2020 To : Board of Directors and President of The Stock Exchange of Thailand

Q2/2020 (Ending June 30, 2020) To Director and Manager of the Stock Exchange of Thailand UBIS (Asia) Public Company Limited (“the Company”) would like to clarify on the performance and the financial

3323 No. PACE IR 2020/01 Date: 25 August 2020 Subject: Explanation of the Operating Results for the three-month period ended 30 September 2019 changing over 20% To: The President The Stock Exchange of

[COMPANY NAME] Ref.: EFORL IR037/2020 September 11, 2020 Subject: Management Discussion and Analysis Quarter 2 Ending 30 June 2020 To President The Stock Exchange of Thailand 1. Overview financial

MD&A Q3_2020 (Eng ) November 2, 2020 Subject : Interim Management Discussion and Analysis of Q3/2020 Attention : President of The Stock Exchange of Thailand We attach herewith the financial

April 27th, 2021 No. ACC/HO 008/64 Topic: Management Discussion and Analysis for the Quarter of 1/2021 To: President The Stock Exchange of Thailand During the first quarter of 2021 a new wave of

Discussion and Analysis, Quarter 1 Ending 31 March 2020 (4) The Impact of the COVID-19 situation To: President of the Stock Exchange of Thailand Reference: (1) Document no. Tor. For. 4/2020 dated April 10

August 11, 2020 Subject: Management’s Discussion and Analysis for the second Quarter of 2020 To: The President The Stock Exchange of Thailand (SET) DOD Biotech Public Company Limited and its subsidiaries

-9320 1 Ref: PCL 2020/018 November 14, 2020 Subject: Management Discussion and Analysis for the 9-month period ended 30 September 2020 To: The President of the Stock Exchange of Thailand Panjawattana